Histomorphometric evaluation of the effects of zoledronic acid on mandibular distraction osteogenesis in rabbits.
OBJECTIVE
To assess the effect of systemic administration of zoledronic acid (ZA) on mineralization of newly formed bone and to determine strain-related osteoporosis on surrounding bone during lengthening of immature rabbit mandible.


METHODS
Eighteen New Zealand white rabbits were divided randomly into 2 groups, and bone lengthening was carried out in the left portion of the mandible through distraction osteogenesis with a rate of 0.5 mm every 12 hours for 5 days. The experimental group was administered 0.1 mg/kg ZA intravenously. The control group was given saline infusion only during operation. All animals were sacrificed at the end of the 28-day consolidation period. The mandibles of all animals were removed and regenerate was evaluated. Osteoblasts, osteoclasts, collagen fibers, and fibroblasts were marked within 0.1-mm(2) area and newly formed bone area was measured within 0.5-mm(2) area. All data were analyzed using Mann-Whitney U test.


RESULTS
Although irregular bone destruction spots were seen in the control group, the experimental group showed regular ossification areas and significant difference between osteoblast and osteoclast numbers (P < .05). In the regenerate zone, there was considerable difference between the 2 groups in terms of osteoblast, osteoclast, and collagen amounts (P < .05). Additionally, newly formed bone areas and fibroblast count were higher in experimental group.


CONCLUSIONS
The results of this study showed that ZA had positive effects on the new bone formation, which may potentially shorten the consolidation period.
Pampu
A Alper
AA
Department of Oral and Maxillofacial Surgery, Karadeniz Technical University, Faculty of Dentistry, Trabzon, Turkey. alperpampu@hotmail.com
Dolanmaz
Doğan
D
Tüz
Hakan H
HH
Avunduk
M Cihat
MC
Kişnişci
Reha S
RS
D000818:Animals; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D001861:Bone Regeneration / Q000187:drug effects*; D002113:Calcification, Physiologic / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003094:Collagen / Q000096:biosynthesis; D003799:Dental Stress Analysis; D004164:Diphosphonates / Q000494:pharmacology*; D005347:Fibroblasts / Q000187:drug effects; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D008334:Mandible / Q000601:surgery; D019186:Mandibular Advancement / Q000009:adverse effects / Q000379:methods*; D010006:Osteoblasts / Q000187:drug effects; D010010:Osteoclasts / Q000187:drug effects; D019857:Osteogenesis, Distraction / Q000009:adverse effects; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control; D011817:Rabbits; D011897:Random Allocation; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D003094:Collagen